KRTX

Karuna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s Psychosis

PremiumCompany Announcements

11d ago

Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT Study

PremiumCompany Announcements

13d ago

Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT Study

PremiumCompany Announcements

18d ago

Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with Phase 3 Study

PremiumCompany Announcements

20d ago

PremiumCompany AnnouncementsKaruna Therapeutics Undergoes Extensive Corporate Transformation

1y ago

Bristol Myers completes acquisition of Karuna Therapeutics

The Fly

Bristol Myers completes acquisition of Karuna Therapeutics

1y ago

Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65)

The Fly

Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65)

1y ago

Neurocrine price target raised to $106 from $100 at Piper Sandler

PremiumThe Fly

1y ago

CERE

Karuna Therapeutics downgraded to Neutral from Buy at Mizuho

PremiumThe Fly

1y ago

The biopharmaceuticals stocks to own in 2024, according to BofA

PremiumThe Fly

2y ago

Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited

JNJ

PremiumThe Fly

2y ago

PremiumThe FlyKaruna Therapeutics price target raised to $330 from $197 at UBS

2y ago

Karuna Therapeutics downgraded to Neutral from Overweight at JPMorgan

The Fly

Karuna Therapeutics downgraded to Neutral from Overweight at JPMorgan

2y ago

RayzeBio deal another ‘incremental positive’ for Bristol, says Morgan Stanley

The Fly

RayzeBio deal another ‘incremental positive’ for Bristol, says Morgan Stanley

2y ago

Karuna downgraded, Arm target raised: Wall Street’s top analyst calls

PremiumThe Fly

2y ago

ARM

M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B

PremiumMarket News

2y ago

AZN

Karuna deal favorable for Axsome Therapeutics, says H.C. Wainwright

PremiumThe Fly

2y ago

Reviva may be most undervalued in neurology, says H.C. Wainwright

AXSM

PremiumThe Fly

2y ago

CERE

PremiumThe FlyKaruna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2y ago

AXSM

Karuna Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

The Fly

Karuna Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

2y ago

Karuna Therapeutics downgraded to Market Perform from Outperform at Leerink

The Fly

Karuna Therapeutics downgraded to Market Perform from Outperform at Leerink

2y ago